- Home
- BMRN vs PPC Comparison
BMRN vs PPC Comparison
Compare BMRN & PPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMRN
- PPC
- Stock Information
- Founded
- BMRN 1996
- PPC 1946
- Country
- BMRN United States
- PPC United States
- Employees
- BMRN 3040
- PPC N/A
- Industry
- BMRN Biotechnology: Pharmaceutical Preparations
- PPC Meat/Poultry/Fish
- Sector
- BMRN Health Care
- PPC Consumer Staples
- Exchange
- BMRN Nasdaq
- PPC Nasdaq
- Market Cap
- BMRN 9.9B
- PPC 9.0B
- IPO Year
- BMRN 1999
- PPC 1987
- Fundamental
- Price
- BMRN $51.46
- PPC $37.05
- Analyst Decision
- BMRN Buy
- PPC Hold
- Analyst Count
- BMRN 19
- PPC 3
- Target Price
- BMRN $90.26
- PPC $47.67
- AVG Volume (30 Days)
- BMRN 2.9M
- PPC 1.8M
- Earning Date
- BMRN 10-27-2025
- PPC 10-29-2025
- Dividend Yield
- BMRN N/A
- PPC 22.67%
- EPS Growth
- BMRN 59.53
- PPC 24.34
- EPS
- BMRN 2.68
- PPC 5.16
- Revenue
- BMRN $3,094,001,000.00
- PPC $18,351,780,000.00
- Revenue This Year
- BMRN $13.32
- PPC $3.98
- Revenue Next Year
- BMRN $7.51
- PPC $0.51
- P/E Ratio
- BMRN $19.20
- PPC $7.18
- Revenue Growth
- BMRN 12.39
- PPC 1.76
- 52 Week Low
- BMRN $50.76
- PPC $35.73
- 52 Week High
- BMRN $73.51
- PPC $57.16
- Technical
- Relative Strength Index (RSI)
- BMRN 40.53
- PPC 32.15
- Support Level
- BMRN $51.80
- PPC $35.73
- Resistance Level
- BMRN $53.49
- PPC $38.26
- Average True Range (ATR)
- BMRN 1.84
- PPC 1.08
- MACD
- BMRN -0.08
- PPC 0.08
- Stochastic Oscillator
- BMRN 12.58
- PPC 36.96
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
About PPC Pilgrim's Pride Corporation
Pilgrim's Pride is the second-largest poultry producer in the US (59% of 2024 sales), the UK (29% including other European sales), and Mexico (12%). Its UK and European arm also includes pork operations from the 2019 acquisition of Tulip. Pilgrim's sells to chain restaurants, food processors, food distributors, and retail chains. Most of its US and Mexican sales come from fresh chicken, while prepared chicken and pork constitute most of its UK and European sales. JBS owns more than 80% of Pilgrim's Pride's outstanding shares, though it failed to acquire the remaining stake in 2021 after a special board committee deemed that JBS' offer undervalued Pilgrim's Pride.